Cyclophosphamide
- PDF / 169,466 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 24 Downloads / 178 Views
1 S
Cardiotoxicity manifesting as left ventricular dysfunction: case report In a retrospective review of six patients, who had undergone haematopoietic stem cell transplantation (HSCT) for systemic sclerosis (SSc) in Sheffield, a 52-year-old man was described, who developed cardiotoxicity in the form of left ventricular dysfunction following treatment with cyclophosphamide. The man, who had previously been treated with hydroxychloroquine, mycophenolate and unspecified steroids for SSc, underwent HSCT in 2019. During this time, he also received cyclophosphamide [route and dosage not stated]. However, he subsequently experienced fatal left ventricular dysfunction. Of note, his pre-procedure screening tests had revealed no evidence of left ventricular dysfunction, pulmonary artery hypertension or interstitial lung disease. Hence, his acute deterioration was attributed to cyclophosphamide cardiac toxicity [duration of treatment to reaction onset not stated], with acute Campylobacter myocarditis as a contributing factor. He died on day 1 post stem cell infusion. Smith R, et al. Haematopoietic stem cell transplantation in systemic sclerosis: Sheffield Teaching Hospitals’s Experience. Rheumatology 59 (Suppl. 2): ii72-ii73 abstr. P149, 803507424 Apr 2020. Available from: URL: http://doi.org/10.1093/rheumatology/keaa111.144 [abstract]
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
